besifovir dipivoxil maleate + L-carnitine

Besifovir dipivoxil maleate + L-carnitine is a **combination oral antiviral therapy** used primarily as a first-line treatment for chronic hepatitis B in South Korea. **Besifovir dipivoxil maleate** is a potent acyclic nucleoside phosphonate prodrug that is converted in vivo to an active guanosine monophosphate analogue, directly **inhibiting the hepatitis B virus (HBV) DNA polymerase** and therefore blocking viral replication[1][4][5]. L-carnitine is included specifically to prevent **carnitine depletion**—an adverse effect observed with besifovir—by supporting fatty acid metabolism within mitochondria and potentially mitigating hepatic steatosis and other metabolic disturbances[1][3][4]. Recent studies have shown this combination suppresses hepatitis B virus with sustained efficacy, no resistance over long-term use, and safety profiles superior to some other nucleos(t)ide analogues with respect to renal and bone health[1][5][6][7].

Brand names

Besifovir

Other names

besifovir + L-carnitinebesifovir dipivoxil maleate + L-carnitine